Premium
Clinical value of botulinum toxin in neurological indications
Author(s) -
Ward A. B.,
Molenaers G.,
Colosimo C.,
Berardelli A.
Publication year - 2006
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2006.01650.x
Subject(s) - blepharospasm , medicine , botulinum toxin , dystonia , cervical dystonia , spasticity , hemifacial spasm , movement disorders , tics , cerebral palsy , weakness , muscle tone , physical medicine and rehabilitation , focal dystonia , anesthesia , surgery , psychiatry , facial nerve , disease
Botulinum toxin type‐A (BoNT‐A) prevents the release of acetylcholine at cholinergic junctions, thereby causing temporary muscle weakness lasting 3–4 months. It is now widely used to treat a broad range of clinical disorders characterized by muscle hyperactivity. BoNT‐A has proved effective in the management of several neurological conditions and, in particular, in the management of movement disorders (e.g. blepharospasm, cervical dystonia, laryngeal dystonia, limb dystonia, hemifacial spasm, focal tics, tremor and other hyperkinetic disorders). As a treatment of spasticity, BoNT‐A can improve mobility and dexterity as well as preventing the development of distressing and costly secondary complications. In cerebral palsy, BoNT‐A is of value, being able to delay or even avoid surgery until motion patterns have become established.